Switching Patients from Originator to Biosimilar Medications in Rheumatoid Arthritis: Limiting the ‘Nocebo’ Effect

European Medical Journal Rheumatology

关键词: Rheumatoid Arthritis;   

DOI  :  

来源: DOAJ

【 摘 要 】

Biosimilars have been available in Europe since 2006, and biosimilars of monoclonal antibodies since 2013, and are now a widespread clinical reality. Since their introduction, various sources of data have become available to help physicians make knowledgeable decisions about their use. For example, randomised clinical trials can demonstrate the comparable efficacy and safety between the biosimilar and its reference biologic. Real-world evidence from registries and individual clinical centres provide additional data on the actual use of biosimilars across different therapeutic indications and broader patient populations, including those who have switched from the reference biologic to the biosimilar, while offering additional understanding of the long-term safety and effectiveness. Well-informed decisions based on a solid understanding of these data are important and can help the physician guide the patient to their own well-informed decision, thereby reducing the possibility of a nocebo effect. Here we review available data sources and look at best practice examples of communicating with patients.

【 授权许可】

Unknown